Article Details
Retrieved on: 2022-02-08 00:26:23
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
That biotech aimed to develop it as a treatment for basal cell carcinoma. Taladegib and other assets went to Roche in 2017 when the Swiss pharma giant ...
Article found on: medcitynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here